Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM

Diabetologia

Volumn 40, Issue 7, 1997, Pages 843-849

  Brussaard, H E ^a,c   Gevers Leuven, J A ^b   Frolich M ^a   Kluft, C ^b   Krans, H M J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

^c VIRGA JESSE HOSPITAL   (Belgium)

Author keywords

Coagulation factors; Fibronolysis; Glucose regulation; Hepatic glucose production; Insulin sensitivity; Lipoprotein profiles; Non insulin dependent diabetes mellitus; Oestrogen therapy

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BLOOD CLOTTING FACTOR; ESTRADIOL; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; ESTROGEN THERAPY; FEMALE; FIBRINOLYSIS; GLUCOGENESIS; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMENOPAUSE; PRIORITY JOURNAL;

C-PEPTIDE; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FATTY ACIDS, NONESTERIFIED; FEMALE; FIBRINOLYSIS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN RESISTANCE; LIPIDS; LIPOPROTEINS; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POSTMENOPAUSE; TISSUE PLASMINOGEN ACTIVATOR; TRIGLYCERIDES;

EID: 8544267912     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250050758     Document Type: Article

References (36)

1. DeFronzo RA, Bonadonna RC, Ferrannini E (1992) Pathogenesis of NIDDM, a balanced overview. Diabetes Care 15: 318-368
2. Kaplan NM (1989) The Deadly Quartet, Upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 149: 1514-1520
3. Bierman EL (1992) Atherogenesis in diabetes. Arterioscler Thromb 12: 647-656
4. Reaven GM (1991) Resistance to insulin-stimulated glucose uptake and hyperinsulinemia: role in non-insulin dependent diabetes, high blood pressure, dyslipidaemia HTG and coronary heart disease. Diab Metab 17: 78-86
5. Juhan-Vague I, Thompson SG, Jespersen J (1993) Involvement of the hemostatic system in the insulin resistance syndrome, a study of 1500 patients with angina pectoris. Arterioscl Thromb 13: 1865-1873
6. Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders AE (1993) The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 42: 945-949
7. Brussaard HE, Gevers Leuven JA, Krans HMJ, Meijer P, Buytenhek R, Kluft C (1994) Non-esterified fatty acids are related with hypofibrinolysis in type 2 diabetes mellitus. Fibrinolysis 8: 25-27
8. DeStefano F, Ford EA, Newman J et al. (1993) Risk factors for coronary heart disease mortality among persons with diabetes. Ann Epidemiol 3: 27-34
9. Assmann G, Schulte H (1989) Diabetes mellitus and hypertension in the elderly: concomitant hyperlipidemia and coronary heart disease risk. Am J Cardiol 63: 33H-37H
10. Barrett-Connor E (1994) Heart disease in women. Fert Ster 62: 127S-132S
11. Nabulsi AA, Folsom AR, White A et al. (1993) For the atherosclerosis risk in communities study investigators. Association of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 328: 1069-1075
12. Ferrara A, Barrett-Connor E, Wingard DL, Edelstein SL (1995) Sex differences in insulin levels in older adults and the effect of body size, oestrogen replacement therapy, and glucose tolerance status. The Rancho Bernardo Study. Diabetes Care 18: 220-225
13. Godsland IF, Gangar K, Walton C et al. (1993) Insulin resistance, secretion and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 42: 846-853
14. Lindheim SR, Presser SC, Ditkoff EC, Vijod MA, Stanczyk FZ, Lobo RA (1993) A possible bimodel effect of oestrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril 60: 664-667
15. Mandour T, Kissebah AH, Wynn V (1977) Mechanisms of oestrogen and progesterone effects on lipid and carbohydrate metabolism: alteration in the insulin : glucagon molar ratio and hepatic enzyme activity. Eur J Clin Invest 7: 181-187
16. Ahmed-Sorour H, Baily CJ (1980) Role of ovarian hormones in the long-term control of glucose homeostasis. Interaction wiht insulin, glucagon and epinephrine. Hormone Res 13: 396-403
17. The writing group for the PEPI trial (1995) Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 273: 199-208
18. Stampfer MJ, Colditz GA, Willett WC et al. (1991) Postmenopausal oestrogen therapy and cardiovascular disease. Ten year follow-up from the nurses' health study. N Engl J Med 325: 756-762
19. Vandenbroucke JP (1995) How much of the cardioprotective effect of postmenopausal estrogens is real? Epidemiology 6: 207-208
20. Adams MR, Kaplan JR, Manuck SB, Koritnik DR, Parks JS, Wolfe MS (1990) Inhibition of coronary artery atherosclerosis by 17 β-oestradiol in ovariectomized monkeys. Lack of an effect of adding progesterone. Arteriosclerosis 10: 1051-1057
21. Collins P, Rosano GMC, Sarrel PM et al. (1995) 17 β-Estradiol attenuates acetylcholine-induced coronary artery constriction in women but not in men with coronary artery disease. Circulation 92: 24-30
22. Gevers Leuven JA (1994) Sex steroids and lipoprotein metabolism. Pharmac Ther 64: 99-126
23. Kroon UB, Silfverstolpe G, Tengborn L (1994) The effects of transdermal oestradiol and oral conjugated oestrogens on haemostasis variables. Thromb Haem 71: 420-423
24. Hemminki E, Sihvo S (1993) A review of postmenopausal hormone therapy recommendations: a potential for selection bias. Obstet Gynecol 82: 1021-1028
25. Godsland IL, Crook D, Simpson R et al. (1990) The effects of different formulations of oral contraceptive agents on Iipid and carbohydrate metabolism. N Engl J Med 323: 1375-1381
26. Gevers Leuven JA, Mooren MV van der, Buytenhek R (1995) The effect of medrogestone on lipids and lipoproteins in postmenopausal women using conjugated oestrogens: an open randomized comparative study. Fertil Steril 64: 525-531
27. Ranby M, Bergsdorf N, Nilsson T, Mellbring G, Winblad B, Bucht G (1986) Age dependence of tissue plasminogen activator concentrations in plasma as studied by an improved enzyme linked immuno-sorbent. Clin Chem 32: 2160-2165
28. Meijer P, Boon R, Jie AFH, Rosen S, Kluft C (1992) Bioimmunoassay for tissue-type plasminogen activator (t-PA) in human plasma: evaluation of blood sampling and handling procedures and comparison with other t-PA activity methods. Fibrinolysis 6: 97-99
29. Ranby M, Sundell IB, Nilsson ThJJ (1989) Blood collection in strong acidic citrate anticoagulants used in a study of dietary influence and basal tPA activity. Thromb Haemost 62: 617-622
30. Brussaard HE, Gevers Leuven AJ, Kluft C, Krans HMJ, Duyvenvoorde W van, Huytenhek R, Laarse A van der, Princen HMG (1997) Effect of 17 β-estradiol on plasma lipids and LDL oxidation in postmenopausal women with type II diabetes mellitus. Arterioscler Throm Vase Biol 17: 324-330
31. Walsh BW, Schiff I. Rosner B, Greenberg L, Ravnikar V, Sacks FM (1991) Effects of postmenopausal oestrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 325: 1196-1204
32. Westerveld HT, Kock-Herman LAW, Rijn JM van, Erkelens DW, Bruin TWA de (1995) 17-beta estradiol improves postprandial lipid metabolism in postmenopausal women. J Clin Endocrin Metab 80: 249-253
33. Krotkiewski M, Seidell JC, Bjorntorp P (1990) Glucose tolerance and hyperinsulinaemia in obese women: role of adipose tissue distribution, muscle fibre characteristics and androgens. J Intern Med 228: 385-392
34. DelPrato S, Bonadonna RC, Bonora E et al. (1993) Characterization of cellular defects of insulin action in type 2 (non-insulin-dependent) diabetes mellitus. J Clin Invest 91: 484-494
35. Walsh BW, Li H, Sacks FM (1994) Effects of postmenopausal hormone replacement with oral and transdermal oestrogen on high density lipoprotein metabolism. J Lip Res 35: 2083-2093
36. Gevers Leuven JA, Kluft C, Dersjant-Roorda MC, Harthoorn-Lasthuizen EJ, Boer R de, Helmerhorst FM (1995) Effects of low-dose ethinylestradiol oral contraceptives differing in progestogenic compound on coagulation and fibrinolytic risk variables for venous and arterial thromboembolic diseases. In: Glas-Greenwalt P (ed.) Fibrinolysis in disease: molecular and hemovascular aspects of fibrinolysis. CRC Press, Boca-Raton, pp 226-234